Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Film Coated Tablets 30 X 200 mg |
|
||
|
Film Coated Tablets 60 X 200 mg |
|
||
|
Film Coated Tablets 90 X 200 mg |
|||
|
Film Coated Tablets 30 X 400 mg |
|
||
|
Film Coated Tablets 60 X 400 mg |
|
||
|
Film Coated Tablets 90 X 400 mg |
|
Dosage
The recommended dose of pazopanib for the treatment of RCC or STS is 800 mg once daily.
Indications
Renal cell carcinoma (RCC): treatment of adults for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.
Soft tissue sarcoma (STS): treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
Contra-Indications
Hypersensitivity to the active substance or to any of the excipients
Special Precautions
Please refer to the license holder for further details.
Side Effects
Please refer to the license holder for further details.
Drug interactions
Please refer to the license holder for further details.
Pregnancy and Lactation
Please refer to the license holder for further details.
Overdose
Please refer to the license holder for further details.
